Table 2 Comparison of clinical features of vitiligo patients with and without anti-thyroid peroxidase antibody
From: Anti-thyroid peroxidase antibody and vitiligo: a controlled study
Clinical features | No. (%) with autoantibodies (17 patients) | No. (%) without autoantibodies (77 patients) |
|---|---|---|
Mean age +/- SD, yr | 26.47 +/-11.52 | 29.16 +/- 16.18 |
Gender | ||
Male | 5 (10.4) | 43 (89.6) |
Female* | 12 (26.1) | 34 (73.9) |
Age (year) | ||
=>17 | 4 (18.2) | 18 (81.8) |
18–25* | 5 (20.8) | 19 (79.2) |
26–35* | 5 (18.5) | 22 (81.5) |
=<36 | 3 (14.3) | 18 (85.7) |
Mean onset age +/- SD,yr | 19.59 +/- 9.5 | 23.59 +/-16.36 |
Mean duration +/- SD,yr | 6.88 +/- 9.9 | 5.62 +/- 6.98 |
Extent (%) | ||
<20 | 12 (17) | 58 (83) |
20–50 | 5 (25) | 15 (75) |
>50 | 0 | 3 (100) |
Type of vitiligo | ||
Generalized | 13 (20.6) | 50 (79.4) |
Non-generalized | 4 (12.9) | 27 (87.1) |